TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Acute toxicity of sorafenib when combined with RT
Endpoint domain: Adverse events/effects
Primary endpoint: Neonatal Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Change in Tumor Size From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Binge eating frequency
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Annual rate of change in UCB-J DVR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal coronary resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurements of vanilloid compound in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Electrical diaphragmatic signal variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilatory profile variations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventricular Capture Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Self-reported Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Physical Activity Assessed by ActiGraph Monitoring Device
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Occurrence of atrial tachyarrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of tachyarrhythmias
Endpoint domain: Adverse events/effects
Primary endpoint: Standard deviation from center of the road
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of off-road events
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with an ACR20 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events assessed by NCI CTCAE
Endpoint domain: Adverse events/effects
Primary endpoint: Executive Language Functions
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Skin Conductance Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change of the gut virome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Driving Performance - Mean Off-Road Glance Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Metamorphopsia index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Scale (mRS) score at 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serial fundus photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Severe systemic inflammatory response syndrome (SIRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Subjects Ready for Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of maximum bowel diameter from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prediction of biopsy and treatment outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in ventilation (L/min) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of upper airway obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the concentration-time curve of dipyridamole in plasma over one dosing interval at steady state (AUCτ,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of dipyridamole in plasma at steady state (Cmax,ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HOMA-IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Disease Stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance at programming session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Iron bio-availability from Oral Iron Supplements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Classification of adverse reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with HIV-1 RNA below 50 copies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Morphological characteristics of vein grafts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Secondary hospitalization(s) or death
Endpoint domain: Mortality/survival
Primary endpoint: Health-Related Quality of Life (1 day)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Time to obtain first target concentration of FK506
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients reaching therapeutic concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportions of Patients With Undetectable Circulating Tumor Cells (CTC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Minimal effective volume of local anesthetic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on visually determination of tooth colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on spectrophotometer determination of tooth colour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on quality of life during treatment and follow-up
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of caries removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in patient reported outcome (PRO) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Autonomous and Controlled Motivation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: medical complications
Endpoint domain: Adverse events/effects
Primary endpoint: Left Ventricle End-Systolic Volume (LV ESV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Degree of physical disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of unexpected cardiac arrest
Endpoint domain: Mortality/survival
Primary endpoint: Exacerbations of sinusitis requiring additional treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Relative peak oxygen consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of PCA morphine usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concordance of MRI type and pathological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quebec Low Back Pain Disability Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-Specific Functional Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: preoperative proteomic profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of At-risk Family Members Who Underwent Cascade Screening
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Performance Endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Levels of phenolic acids and flavonoids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy of ASP2151 compared to valacyclovir
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ASP2151 compared to valacyclovir
Endpoint domain: Adverse events/effects
Primary endpoint: Severe postoperative opioid-related adverse event
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic specificity of COVID VIRO®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic sensitivity of COVID VIRO®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants with Administration (Injection) Site Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Response rates for weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart rate (BPM) during atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Individual Risk Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Systemic Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Eyes With Ocular Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: 6 Minutes Walking Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility as measured by rate of recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with accurate warfarin dosing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent change in weekly average steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy evaluation using RECIST v1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Positive bacterial culture from a normally sterile site
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Subjects With Study Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Halimeter measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body image dissatisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes from baseline in sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes from baseline in potassium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence rate of SIRS
Endpoint domain: Adverse events/effects
Primary endpoint: Change in pain on the visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in anxiety on the State Trait Anxiety Inventory (STAI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ctrough(ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-τ, ss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of alive patients without disease progression
Endpoint domain: Mortality/survival
Primary endpoint: bladder cancer recurrence rate
Endpoint domain: Mortality/survival
Primary endpoint: Absence of insufficient Rome III Diagnostic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, Y, and W
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Patients With Complete Renal Response (CRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Frequency of thrombophilic risk factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mixed venous O2 pressure (PVO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen saturation (O2 Sat) from VBG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Three minute walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Serum Creatinine Tests Ordered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change From Baseline in A1C Levels at Week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of cases of active tuberculosis disease
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases of subclinical tuberculosis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of cases of latent tuberculosis infection
Endpoint domain: Adverse events/effects
Primary endpoint: Levels of micafungin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood conservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Symptomatic major venous thromboembolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in FASD Birthrate Levels
Endpoint domain: Mortality/survival
Primary endpoint: Knee KOOS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: IKDC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: waist circumstance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intra- and inter-observer variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Grade II and IV Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of MDS Patients With Complete Remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of AML Patients With Complete Remission With Incomplete Blood Count Recovery (CRi)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: change in keratometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overactive Bladder Symptom Scale (OABSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum Measured Concentration of Idarucizumab in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of Idarucizumab in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Idarucizumab Eliminated in Urine Over the Time Interval From 0 to 72 Hours (h) (Ae0-72)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior during assisted bathing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Positivity of the rapid diagnostic test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Antimicrobial Therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Gross Total Resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Residual Adenoma Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Zurich Pituitary Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cycle 1 Sensory Neuropathy Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Change From Baseline in the Number of Monthly Cumulative Headache Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in plasma growth hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Count of Participants Achieving 6-month Sustained Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Crestal Bone Level Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: violence behaviors
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of current tobacco use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival Without Grade 3 or 4 Toxicity
Endpoint domain: Mortality/survival
Primary endpoint: Biochemical Failure free Survival (BFFS)
Endpoint domain: Mortality/survival
Primary endpoint: Transient decrease in oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline of progesterone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Satisfaction with timing of contraceptive administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Continuation rate of contraceptive method
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Active Symptoms of Generalized Anxiety Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Acquired Pneumonia Occurrences
Endpoint domain: Adverse events/effects
Primary endpoint: variation of onco suppressor protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores due to intravenous catheterisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain scores due to pin-prick with a 27G needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EGFR mutations rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Modified Medical Research Council (mMRC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in CATᵀᴹ (COPD Assessment Test) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of temozolomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endotoxin activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PDAY score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in urinary nerve growth factor (NGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiovascular Disease Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Clinician Administered PTSD Scale (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Inventory of Interpersonal Functioning (IIP-32)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: prolonged length of stay in the ICU
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Response rate after primary chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 years failure free survival
Endpoint domain: Mortality/survival
Primary endpoint: Rate of histopathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quality of life (QLQ-LC13)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Elevated HBA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of stent fracture
Endpoint domain: Adverse events/effects
Primary endpoint: Partial or complete remission of the vasculitides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Changes in Mitral flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in pulmonary vein flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in left atrial appendage flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Major Symptom Complex (MSC) Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: clinical-pharmacological safety-efficacy profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Visual Analog Scale (VAS) Score for Rating of Pain at the Injection Site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline in Suicidal Ideation Intensity Total Score Via Columbia-suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Function at >16 years
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in infant expressive vocabulary
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline Capture Task Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline N2pc Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline Filter Task Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline CDA Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: score of the self QoL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline FCL Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life